Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VBC117 in Advanced Solid Tumors
NCT07772934Phase 2Not yet recruiting
- Sponsor
- VelaVigo
- Start
- Aug 2026
- Primary completion
- Feb 2029
- Countries
- 2
01
Overview
Phase 2, open-label trial of VBC117 in solid tumor (5 arms), sponsored by VelaVigo. Primary endpoints: Incidence of Adverse Events, Incidence of Dose-Limiting Toxicities at 21 days and 3 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
VBC117
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07772934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07772934.